论文部分内容阅读
一线使用吉西他滨已成为晚期胰腺癌治疗的标准方案,但是目前尚无标准的二线化疗方案。支持二线治疗优于最佳支持治疗的数据少之又少。我们总结已公布的二线化疗方案,大部分为Ⅱ期临床试验,以摘要的形式发表居多,没有单药的广泛研究。以药物的副作用作为代价,二线化疗的益处是非常有限的,但Ⅲ期随机试验还需要继续进行。未来的二线化疗将不仅以有效率或生存期作为评价,还将把临床受益率作为治疗目标。
First-line use of gemcitabine has become the standard treatment for advanced pancreatic cancer, but there is currently no standard second-line chemotherapy. There is very little data to support second-line therapy over optimal supportive care. We conclude the published second-line chemotherapy regimens, most of which are Phase II clinical trials, published mostly in the form of abstracts, without extensive studies on single drugs. The benefits of second-line chemotherapy are very limited at the expense of drug side effects, but the Phase III randomized trials also need to be continued. Future second-line chemotherapy will not only be evaluated as effective or survival but will also target clinical benefit rates.